Skip to main content

Victory Square Technologies Portfolio Company is the first to be approved by the São Paulo State Government Covid-19 Innovation Programme

VANCOUVER, British Columbia, Aug. 27, 2020 (GLOBE NEWSWIRE) — Victory Square Health Inc./Safetest (“VS Health” or the “Company“) – portfolio company of Victory Square Technologies Inc. (“Victory Square“) (CSE:VST) (OTC:VSQTF) (FWB:6F6)  creator of the only Covid-19 Testing product approved in the Ideiagov program supported by the São Paulo State Government for immediate trials and application in the State to start August 28, 2020.The Analysis Committee comprised of the Economic Development Secretariat and published in the official Gazette of the State of São Paulo met on July 31, 2020 with the objective of evaluating the proposals from companies vying for the opportunity to have their Covid-19 products approved.The proposals were analyzed in three separate phases to select a Covid-19 test that is reliable and cost effective for the purposes of being used in a public health program. Victory Square Health/Safetest was selected as their first choice.Stage one consisted of an initial screening to analyze the adequacy of the product. The second stage required the opinions from registered technicians while also analyzing proposed products. The third and final stage verified the relevance, adequacy, and merit of the proponent.In this program, VS Health/Safetest will have access to specialists from Hospital das Clínicas, the São Paulo State Health Department, the São Paulo Institute of Technological Research – IPT and the São Paulo State Data Processing Company – PRODESP, for guidance and support in the implementation of pilot projects, in addition to the use of laboratory infrastructure. Also, will apply the solution in real-life environments to validate the solution at Hospital das Clínicas and other agencies, providing scalability in the public health system.As of August 26, 2020 Brazil has recorded 3.72 million Covid 19 cases with 118,000 deaths.  The state of São Paulo has reported 776,000 Covid-19 cases and 29,194 deaths. The São Paolo State figures represent 27% of the entire Covid-19 cases and deaths in Brazil.This initial approval of the Safetest Covid-19 antibody test by The São Paulo Government will give the company an exclusive start for application in São Paulo and for opportunities for further growth and contracts, financing, and related expansion of their exclusive product.Victory Square Health/Safetest’s Covid-19™ test products were featured in Forbes Brasil (https://forbes.com.br/) in June 2020.Disclaimer:

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.